PK & property differences of biologics & small molecule drugs
5:26
the direct & indirect PK/PD models & dose fractionation studies
12:59
discovery of nivasorexant, an orexin-1 receptor antagonist
11:16
FDA approval of EXBLIFEB - cefepime & enmetazobactam
10:00
FDA approval of TRYVIO - aprocitentan
10:26
FDA approval of REZDIFFRA (resmetirom) for NASH/MASH treatment
36:54
Dec. CGR | Nutritional Impact of SUD on the Body & How to Eat a Well-balanced Diet to Help Recovery
18:18
Identify Promising Novel Leads: Integrated HTS platform powered by computational chemistry and AI/ML
20:46